Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

QUADRAMET

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

Standard Dose
50mCi/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview QUADRAMET is listed in Drugs@FDA under application 020570 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient SAMARIUM SM-153 LEXIDRONAM PENTASODIUM Form and strength INJECTABLE;INJECTION - 50mCi/ML Sponsor LANTHEUS MEDICAL Submission history Latest submission status date: 2017-09-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview QUADRAMET is listed in Drugs@FDA under application 020570 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient SAMARIUM SM-153 LEXIDRONAM PENTASODIUM Form and strength INJECTABLE;INJECTION - 50mCi/ML Sponsor LANTHEUS MEDICAL Submission history Latest submission status date: 2017-09-21 00:00:00. Submission type: SUPPL.

Monitoring

  • Marketing status: Discontinued
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
QUADRAMET (SAMARIUM SM-153 LEXIDRONAM PENTASODIUM) | Drug Monograph | MedicHelpline